Sustained-release formulations for treating CNS-mediated disorders
US7235258B1 · kind B1 · utility
13Cited by
13References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 19, 2000 |
| Grant date | Jun 26, 2007 |
| Priority date | — |
| Expiry date | Oct 19, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/5073
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Sustained-release compositions for delivering therapeutic concentrations of isovaleramide, isovaleric acid, and certain structurally related compounds are provided for the treatment for a variety of pathological conditions, including epilepsy and spasticity, which are ameliorated by effecting a modulation of CNS activity. The ability of the compositions to sustain relatively constant levels of the drug at a therapeutic dose in the serum for extended periods of time enables a once or twice daily administration schedule.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.